scholarly journals BRAF-mutant melanoma of the skin during pregnancy with dichorionic diamniotic twins. Clinical case

MD-Onco ◽  
2021 ◽  
Vol 1 (1) ◽  
pp. 38-42
Author(s):  
M. M. Davydov ◽  
P. A. Zeynalova ◽  
A. A. Fedenko ◽  
D. A. Chekiny ◽  
E. K. Ibragimov ◽  
...  
Keyword(s):  
Lymph Node ◽  
Clinical Case ◽  
Retrospective Studies ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Malignant Neoplasms ◽  
Node Dissection ◽  
Child Bearing ◽  
Braf Mutant ◽  
Conclusive Data

Per the majority of authors, melanoma is the most common tumor diagnosed during pregnancy (31 % of all malignant neoplasms). In approximately 1/3 of women melanoma developed in child-bearing age is diagnosed during pregnancy or in the postpartum period. However, only some retrospective studies analyzed the effect of pregnancy on melanoma development, and conclusive data on development, progression and treatment of BRAF-mutant melanoma is lacking. In this subpopulation of patients, BRAF status supposedly can negatively affect disease outcome irrespective of treatment methods.The article presents a clinical case of recurrence of melanoma with the BRAF V600E mutation during pregnancy. The patient underwent lymph node dissection during pregnancy prolongation, after labor she received antitumor drug therapy with МЕК and ВRAF inhibitors. Melanoma recurrence during pregnancy did not worsen treatment outcomes for the mother and embryo.

BRAF V600E Mutation Independently Predicts Central Compartment Lymph Node Metastasis in Patients with Papillary Thyroid Cancer

2012 ◽  
Vol 20 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Gina M. Howell ◽  
Marina N. Nikiforova ◽  
Sally E. Carty ◽  
Michaele J. Armstrong ◽  
Steven P. Hodak ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Papillary Thyroid Cancer ◽  
Central Compartment ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Node Metastasis

Mcl-1 Expression May Be Associated With Favorable Clinical Outcome in BRAF V600E–Mutated MMR-Deficient Colorectal Cancers

2019 ◽  
Vol 152 (Supplement_1) ◽  
pp. S58-S59
Author(s):  
Xin Zhang ◽  
Jennifer Findeis-Hosey ◽  
Meenal Sharma ◽  
Raul Gonzalez ◽  
Rebecca Amorese ◽  
...  
Keyword(s):  
Lymph Node ◽  
Clinical Outcome ◽  
Lymphovascular Invasion ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Positive Staining ◽  
Lower Grade ◽  
Ajcc Stage ◽  
Pathologic Features ◽  
Favorable Clinical Outcome

Abstract Objectives The BRAF V600E mutation is associated with treatment resistance and is a poor prognostic indicator in colorectal adenocarcinomas (CRAs). Prior studies have shown that the BRAF V600E mutation confers resistance to apoptosis by Mcl-1 gene upregulation. We evaluated the clinical effect of Mcl-1 expression on BRAF-mutated (BM) MMR-deficient (dMMR) CRAs. Methods Thirty-one BM dMMR CRAs were included in a tissue microarray. The intensity and extent of Mcl-1 expression were evaluated by immunohistochemistry. Staining intensity (0-3+) and percentage of cells with positive staining (none, <10% = 1, 10%-50% = 2, and >50% = 3) were determined. Cases were considered positive when the intensity score multiplied by the percentage category score was >4. Mcl-1 expression was correlated with clinicopathologic features. Results Positive Mcl-1 staining was identified in 13 (42%), among which 9 (69.2%) were well to moderately differentiated with lymphovascular invasion present in 4 (30.8%), lymph nodes metastases in 3 (23.1%), and AJCC stage pT3 or greater in 8 (61.5%). In contrast, 18 (58%) were Mcl-1 negative, among which 10 (55.6%) were poorly differentiated with lymphovascular invasion present in 12 (66.7%), lymph node metastases in 9 (50%), and AJCC stage pT3 or greater in 14 (77.8%). Conclusion Among 31 examined BM dMMR CRAs, cases that demonstrated Mcl-1 expression were associated with a lower grade, lower rate of lymphovascular invasion and lymph node metastasis, and lower AJCC stage. While Mcl-1 expression confers resistance to apoptosis, this study suggests that Mcl-1–positive tumors demonstrate pathologic features associated with a favorable clinical outcome.

scholarly journals Comprehensive evaluation of risk factors for lymph node metastasis with papillary thyroid carcinoma in Southwest China patients

2020 ◽  
Author(s):  
Yan Dong ◽  
Dan Wang ◽  
Yisheng Luo ◽  
Ling Chen ◽  
Huili Bai ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lymph Node ◽  
Protective Factor ◽  
Southwest China ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Papillary Thyroid ◽  
Wild Type ◽  
Node Metastasis ◽  
Significant Difference

Abstract Background: With the increasing incidences of papillary thyroid cancer(PTC), it is important to risk-stratify patients who may have more aggressive tumor biology. This study aimed to evaluate the risk factors for lymph node metastasis with PTC in Southwest China Patients which may provide a substantial reference for clinical diagnosis and treatment. Methods: 1045 PTCs (313 PTMC and 732 non-PTMC) between August 2016 and August 2019 were examined totally (including one Tibetan). BRAF V600E mutation was tested in all samples. The clinical data (gender, age, tumor location, sample source and pathological features) were retrospectively analyzed. Logistic regression analysis was performed to evaluate independent risk factors for LNM. Results: 181 out of 313 PTMC cases (57.8%), 145 out of 732 non-PTMC cases (19.8%) had BRAF V600E mutation, the Tibetan had a double mutation of BRAF L597Q and V600E in two separate lesions. In PTMC, significant difference in gender and sample source was found (BRAF V600E mutation vs. wild-type). In non-PTMC, significant difference in gender was found (BRAF V600E mutation vs. wild-type). The female (OR=1.952; 95% CI= 1.373-2.774; P= 0.00), age (31-59 years) and diameter of tumor ≤1cm (OR=3.273; 95% CI= 2.417-4.432; P=0.000) were significant independent predictors of LNM in all PTCs. In PTMC, the female (OR= 3.002; 95% CI= 1.654-5.446; P= 0.00) was a significant independent predictor of LNM. The tumor in left and right lobes simultaneously was an independent protective factor of LNM in each group (PTCs: OR=0.287; PTMC: OR=0.170; non-PTMC: OR=0.441, respectively). The BRAF V600E mutation rate of US-FNAC was much higher than FFPE in PTMC (P=0.018). Conclusions: Unlike previous research, our findings suggested that the female patients and diameter of tumor ≤1cm were risk factors for LNM and the BRAF V600E wild-type of PTMC might be more aggressive than others. Interestingly, the position of tumor in bilateral thyroid simultaneously was an independent protective factor for LNM. The US-FNA should be recommended for gene analysis (BRAF V600E) in PTMC. The BRAF L597Q mutation may be an independent aggressive factor in the Chinese Tibetan population. Hence, clinicians should consider an individualized treatment according to gene mutation, gender, age, tumor size and location of tumor in order to achieve a better therapeutic efficacy.

Clinicopathologic features and impact of metastasectomy in patients with BRAF-mutant metastatic colorectal cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15547-e15547
Author(s):  
Jianwei Zhang ◽  
Cailu Shen ◽  
Jianxia Li ◽  
Zehua Wu ◽  
Huabin Hu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Metastatic Colorectal Cancer ◽  
Systemic Treatment ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Clinicopathologic Features ◽  
Significant Difference ◽  
The Impact ◽  
Braf Mutant

e15547 Background: BRAF V600E mutation is associated with poor prognosis in patients with metastatic colorectal cancer (mCRC), while the non-V600E mutation mCRC patients showed better prognosis than that of V600E mutation. The clinicopathologic features between V600E and non-V600E mutation has not yet been fully evaluated. And the impact of metastasectomy for patients with BRAF-mutant mCRC was not well-known. Methods: A retrospective study was conducted to evaluate the clinical and pathological characteristics of patients with BRAF-mutant mCRC. Next generation sequencing (22-gene panel) was performed in some of the patients. Survival was also analyzed in the cohort of BRAF V600E and non-V600E mutation with or without metastasectomy. Results: Between December 2014 and August 2020, 116 patients with BRAF-mutant mCRC were enrolled, including 94 patients with BRAF V600E mutation and 22 patients with non-V600E mutation. Significant difference was observed in the prevalence of peritoneal metastasis (69.1% vs. 27.3%, P = 0.001) and lung metastasis (11.7% vs. 36.4%, P = 0.009) between BRAF V600E mutation and non-V600E mutations. In genomic profile, SMAD4 mutation (30.7% vs. 13.7%) showed higher prevalence in patients with BRAF V600E mutation than that of non-V600E mutations, while RAS mutation (18.2% vs. 6.4%) and FBXW7 mutation (13.7% vs 3.1%) had higher incidence in BRAF non-V600E mutations than that of V600E mutation. Patients with BRAF V600E mutation showed a poorer overall survival than those with non-V600E mutations (13.9 vs. 26.8 months, P = 0.038). Totally, 46 patients received metastasectomy after systemic treatment. The median survival for BRAF V600E patients with or without metastasectomy was not reach (42.3+ months) vs. 8.3 months, respectively ( P < 0.001), and for non-V600E patients with or without metastasectomy was not reach (64.2+ months) vs. 23.3 months, respectively (P < 0.001). In multivariate analysis, ECOG performance status (0-1 vs. 2) ( P = 0.001), Staging (IVa-b vs. IVc) ( P = 0.01) and metastasectomy ( P = 0.001) were independent prognostic factors of overall survival. Conclusions: BRAF V600E mutation defines a subgroup of mCRC with worse prognosis. Metastasectomy might improve the survival benefit in carefully selected BRAF-mutant mCRC patients after systemic treatment.

Axillary Dissection

2019 ◽  
pp. 635-640
Author(s):  
Ashkaun Shaterian ◽  
Erin Lin
Keyword(s):  
Lymph Node ◽  
Axillary Lymph Node ◽  
Axillary Dissection ◽  
Lymph Node Biopsy ◽  
Malignant Neoplasms ◽  
Axillary Lymph ◽  
Node Dissection ◽  
Subclinical Disease ◽  
Therapeutic Value ◽  
Pathologic Staging

Axillary dissection represents an evaluation of the axillary lymph node basin to provide prognostic and therapeutic value for cancer patients. Axillary lymph node dissection (ALND) is most commonly utilized in breast cancer but has applications in the treatment of other malignant neoplasms that may drain to the axillary lymphatics. ALND offers pathologic staging of cancer, therapeutic removal of clinically apparent axillary disease, and the removal of lymph nodes with possible subclinical disease following sentinel lymph node biopsy. The anatomy of the axillary space and technique of axillary dissection are discussed in detail in the chapter text.

A screening test for BRAF mutant melanoma: Immunohistochemical (IHC) analysis of BRAF V600E mutation.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e21076-e21076
Author(s):  
Tomas Lyons ◽  
Odharnaith O'Brien ◽  
Sandra Murphy ◽  
Richard Bambury ◽  
Deirdre O'Mahony ◽  
...  
Keyword(s):  
Screening Test ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Braf Mutant
Sign in / Sign up

Export Citation Format

Share Document